Skip to main content
. 2024 Mar 10;14(6):30087. doi: 10.34172/bi.2024.30087

Fig. 2.

Fig. 2

The utilization of the CRISPR-Cas9 tool shows promise in treating various solid tumors ‎by effectively targeting oncogenes and tumor-suppressor genes in cancer therapies, including ‎those for breast, lung, liver, prostate, and colon cancers. Cas9 has extensively improved or ‎suppressed the activity of different oncogenes and reduced tumor growth.‎